These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31635973)

  • 1. Immune checkpoint inhibitors: For how long do we need to release the brakes to achieve the optimum acceleration of immune-mediated anti-tumor response?
    Sukari A; Nagasaka M
    Oral Oncol; 2020 Feb; 101():104435. PubMed ID: 31635973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
    Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.
    Ackermann CJ; Reck M; Paz-Ares L; Barlesi F; Califano R
    Lung Cancer; 2019 Aug; 134():245-253. PubMed ID: 31319988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma.
    Shaikh FY; Gills JJ; Sears CL
    EBioMedicine; 2019 Oct; 48():642-647. PubMed ID: 31597596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current strategies incorporating immune checkpoint inhibitors for the treatment of advanced or metastatic non-small-cell lung cancers.
    Motta G; Vigneri P
    Future Oncol; 2019 Sep; 15(27):3097-3101. PubMed ID: 31573839
    [No Abstract]   [Full Text] [Related]  

  • 7. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Schvartsman G; Peng SA; Bis G; Lee JJ; Benveniste MFK; Zhang J; Roarty EB; Lacerda L; Swisher S; Heymach JV; Fossella FV; William WN
    Lung Cancer; 2017 Oct; 112():90-95. PubMed ID: 29191606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
    Puri S; Shafique M; Gray JE
    Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
    Santana-Davila R; Chow LQ
    Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
    [No Abstract]   [Full Text] [Related]  

  • 10. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
    J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. There and back again: An immunotherapy tale.
    Guo Y; Krupnick AS
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
    [No Abstract]   [Full Text] [Related]  

  • 12. A Career in Lung Cancer: Pushing Beyond Chemotherapy.
    Patil PD; Shepherd F; Johnson DH
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():583-589. PubMed ID: 31099660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.
    Gion M; Remon J; Caramella C; Soria JC; Besse B
    Lung Cancer; 2017 Jun; 108():72-74. PubMed ID: 28625652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
    Tachihara M; Negoro S; Inoue T; Tamiya M; Akazawa Y; Uenami T; Urata Y; Hattori Y; Hata A; Katakami N; Yokota S
    BMC Cancer; 2018 Oct; 18(1):946. PubMed ID: 30285770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer.
    Dong J; Li B; Zhou Q; Huang D
    J Evid Based Med; 2018 Nov; 11(4):278-287. PubMed ID: 30444051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics.
    Claret L; Jin JY; Ferté C; Winter H; Girish S; Stroh M; He P; Ballinger M; Sandler A; Joshi A; Rittmeyer A; Gandara D; Soria JC; Bruno R
    Clin Cancer Res; 2018 Jul; 24(14):3292-3298. PubMed ID: 29685883
    [No Abstract]   [Full Text] [Related]  

  • 17. Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature.
    Carausu M; Beddok A; Langer A; Girard N; Bidard FC; Massiani MA; Ricard D; Cabel L
    J Immunother Cancer; 2019 Nov; 7(1):317. PubMed ID: 31753021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.
    Song P; Cui X; Bai L; Zhou X; Zhu X; Zhang J; Jin F; Zhao J; Zhou C; Zhou Y; Zhang X; Wang K; Wang Q; Yu Y; Zhang X; Bai C; Zhang L
    Thorac Cancer; 2019 May; 10(5):1303-1309. PubMed ID: 31016875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.
    Ettinger DS; Aisner DL; Wood DE; Akerley W; Bauman J; Chang JY; Chirieac LR; D'Amico TA; Dilling TJ; Dobelbower M; Govindan R; Gubens MA; Hennon M; Horn L; Lackner RP; Lanuti M; Leal TA; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Patel SP; Reckamp K; Riely GJ; Schild SE; Shapiro TA; Stevenson J; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M
    J Natl Compr Canc Netw; 2018 Jul; 16(7):807-821. PubMed ID: 30006423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
    Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.